Acquired Resistance to Therapy Network (ARTNet)

The purpose of this Notice is to announce the NCI's intention to issue a Funding Opportunity Announcement (FOA) that invites applications for Acquired Resistance to Therapy Network (ARTNet). The ARTNet FOA is a reissuance of RFA CA-17-009, which created a Drug Resistance and Sensitivity Network (DRSN) as part of the Cancer Moonshot initiative to accelerate clinical research on drug combinations. While precision oncology approaches are helpful for patient selection based on intrinsic mutations, few strategies exist for acquired resistance including a paucity of research platforms developed from resistant-recurrent tumors. The purpose of the ARTNet is to build upon the DRSN and reprioritize focus on addressing the mechanistic underpinnings of acquired resistance to the full range of treatment modalities (e.g., radiation, chemotherapeutics, targeted agents, immuno-oncology tactics, combined modality treatments).

  • RFA-CA-21-052 Acquired Resistance to Therapy Network (ARTNet; U54 Clinical Trial Not Allowed)
  • RFA-CA-21-053 Coordinating and Data Management Center for Acquired Resistance to Therapy Network (ARTNet; U24 Clinical Trial Not Allowed)